We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.38 | -0.84% | 44.60 | 45.19 | 44.40 | 45.06 | 5,172,442 | 01:00:00 |
From May 2019 to May 2024
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said that its majority-owned joint venture ViiV Healthcare has been granted marketing authorization by the European Commission for its HIV treatment Juluca.
Juluca has been approved for HIV-1 in adults who are virologically suppressed and who have been on an antiretroviral treatment regimen for at least six months, the GlaxoSmithKline said.
The treatment consists of two drugs in a single pill.
ViiV Healthcare Chief Executive Deborah Waterhouse said the decision will allow patients to access a complete treatment program that maintains low levels of the autoimmune virus with a single pill.
Pfizer Inc. (PFE) and Shionogi Limited are minority shareholders in ViiV Healthcare.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
May 21, 2018 06:34 ET (10:34 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
